STOCK TITAN
  1. Home
  2. Sec-filings
  3. TVTX
  4. [Form 4] Travere Therapeutics, Inc. Insider Trading Activity

Travere Therapeutics (TVTX) director granted shares and 12,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Travere Therapeutics director John A. Orwin reported equity awards. He received 4,000 shares of common stock as an automatic equity grant under Travere’s 2018 Equity Incentive Plan, pursuant to the non-employee director compensation program. Following this award, he directly holds 39,375 common shares.

Orwin was also granted stock options for 12,000 shares of common stock at an exercise price of $42.26 per share. These options begin exercisability on May 19, 2027, expire on May 19, 2036, and the equity award vests over one year.

Positive

  • None.

Negative

  • None.
Insider Orwin John A
Role null
Type Security Shares Price Value
Grant/Award Stock option (right to buy) 12,000 $0.00 --
Grant/Award Common Stock 4,000 $0.00 --
Holdings After Transaction: Stock option (right to buy) — 12,000 shares (Direct, null); Common Stock — 39,375 shares (Direct, null)
Footnotes (1)
  1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. The equity award vests over a one year period.
Stock grant 4,000 shares Automatic equity grant of common stock on May 19, 2026
Options granted 12,000 options Stock options (right to buy) granted on May 19, 2026
Option exercise price $42.26 per share Conversion or exercise price for 12,000 options
Shares after grant 39,375 shares Total common shares directly held after stock grant
Option exercisability date May 19, 2027 Exercise date for 12,000 stock options
Option expiration May 19, 2036 Expiration date for 12,000 stock options
Vesting term One year Equity award vests over a one-year period
Automatic equity grant financial
"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended"
2018 Equity Incentive Plan financial
"under the Issuer's 2018 Equity Incentive Plan, as amended"
non-employee director compensation program financial
"pursuant to the non-employee director compensation program"
Stock option (right to buy) financial
"Stock option (right to buy) with an exercise price of 42.2600"
equity award vests financial
"The equity award vests over a one year period"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Orwin John A
(Last)(First)(Middle)
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DR., SUITE 300
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/19/2026A4,000(1)(2)A$039,375D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy)$42.2605/19/2026A12,000(1)05/19/2027(2)05/19/2036Common Stock12,000$012,000D
Explanation of Responses:
1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
2. The equity award vests over a one year period.
/s/ Elizabeth E. Reed, Attorney-in-Fact05/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did John A. Orwin receive from Travere Therapeutics (TVTX)?

John A. Orwin received 4,000 shares of Travere common stock and stock options for 12,000 shares. The stock was an automatic equity grant, and the options provide a right to buy shares at a fixed exercise price.

What is the exercise price and term of John A. Orwin’s new Travere stock options?

The new stock options have an exercise price of $42.26 per share and cover 12,000 shares. They become exercisable starting May 19, 2027, and will expire on May 19, 2036, if not exercised earlier under the specified terms.

How many Travere Therapeutics shares does John A. Orwin hold after this Form 4?

After the reported grant, John A. Orwin directly holds 39,375 shares of Travere common stock. This reflects his post-transaction ownership following the 4,000-share automatic equity award disclosed, separate from the 12,000 stock options also granted.

Is John A. Orwin’s Travere equity grant part of a compensation program?

Yes. The filing states the 4,000-share grant is an automatic equity grant under Travere’s 2018 Equity Incentive Plan. It is made pursuant to the company’s non-employee director compensation program, indicating it is a standard component of board compensation.

How does the vesting work for John A. Orwin’s new Travere equity award?

The filing notes that the equity award vests over a one-year period. This means the granted equity, including the stock or related awards, becomes fully earned gradually across that year, subject to the plan’s detailed terms and continued service conditions.